SHY Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

SHY Therapeutics General Information

Description

Developer of small molecule therapeutics designed to utilize GTP as a source of energy. The company's therapeutics compete with GTP binding to the GTP-binding site of wild-type K-Ras, K-Ras mutants, and other members of the Ras superfamily, enabling clients to demonstrate biological activity and efficacy in models across a large range of diseases.

Contact Information

Website
www.shytherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • 7 Dana Road
  • Valhalla
  • New York, NY 10595
  • United States
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 7 Dana Road
  • Valhalla
  • New York, NY 10595
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SHY Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Startup
To view SHY Therapeutics’s complete valuation and funding history, request access »

SHY Therapeutics Patents

  • 73

    Total Documents Applications and Grants

  • Total Patents Families

  • 45

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

SHY Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024360599-A1 Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins Pending 10-Oct-2023
EP-4791740-A1 Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins Pending 10-Oct-2023
WO-2025080653-A1 Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins Inactive 10-Oct-2023
JP-2026537730-A Pyrrolo[2,1-f][1,2,4]triazine compounds that act against cancer, inflammatory diseases, and fibrotic diseases through interactions with ras superfamily proteins. Pending 10-Oct-2023
JP-2025512935-A Compounds that interact with ras superfamily proteins for the treatment of cancer, inflammatory diseases, ras diseases, and fibrotic diseases Pending 08-Apr-2022 C07D487/04
To view SHY Therapeutics’s complete patent history, request access »

SHY Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioInc@NYMC Accelerator/Incubator
To view SHY Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

SHY Therapeutics FAQs

  • When was SHY Therapeutics founded?

    SHY Therapeutics was founded in 2015.

  • Where is SHY Therapeutics headquartered?

    SHY Therapeutics is headquartered in New York, NY.

  • What industry is SHY Therapeutics in?

    SHY Therapeutics’s primary industry is Drug Discovery.

  • Is SHY Therapeutics a private or public company?

    SHY Therapeutics is a Private company.

  • What is SHY Therapeutics’s current revenue?

    The current revenue for SHY Therapeutics is .

  • Who are SHY Therapeutics’s investors?

    BioInc@NYMC has invested in SHY Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process